New report evaluating pathology capacity in the UK endorses NCRI CM-Path initiative

cm-path_colour_rgbA new report published by Cancer Research UK highlights the importance of initiatives like the NCRI’s Cellular and Molecular Pathology (CM-Path) Initiative to future proof pathology and help address gaps in the UK’s diagnostic pathology services.

‘Testing Times to come: An evaluation of Pathology Capacity across the UK’, published today (23 November 2016), focuses on pathology services provision for cancer diagnosis and care, and is based on a combination of data analysis, desk research and interviews with pathology and diagnostic staff in the healthcare sector and other key stakeholders in each of the four UK nations.

The report sets out 9 recommendations for how pathology capacity in the UK could be improved to meet increasing demand for diagnostic services, including an endorsement of the NCRI’s CM-Path initiative. Through consultation with the research community, CM-Path has identified four priority workstreams to address skills and capacity, clinical trials, discovery and technology and informatics.

Karen Kennedy, NCRI Director said; ‘We are delighted that CRUK’s report reinforces the critical need for the CM-Path initiative, which aims to enhance skills and capacity within the academic pathology workforce and to reinvigorate academic pathology research, both of which are fundamental to successful pathology practice.

‘The NCRI CM-Path initiative, financially supported by 10 NCRI Partners, across the charity and government sectors, was launched in June this year and is already making significant progress.’

The CM-Path Chairperson, Dr Karin Oien, Clinical Senior Lecturer in Pathology at the Institute of Cancer Sciences, University of Glasgow said, ‘Through the CM-Path initiative we are bringing inspiring colleagues, funders and partner organisations together to make a real difference in pathology research.

‘Together, we’ll work to reinvigorate UK academic pathology by building back capacity and expertise, to drive and support innovation’.


Note: The CM-Path initiative is supported by Bloodwise, Breast Cancer Now, Cancer Research UK, Chief Scientist Office, Department of Health, Health Care and Research Wales, Health and Social Care in Northern Ireland, Medical Research Council, Prostate Cancer UK and Tenovus Cancer Care.

The full CRUK report can be found here: http://www.cancerresearchuk.org/about-us/we-develop-policy/our-policy-on-early-diagnosis/our-policy-on-pathology-capacity

The CRUK press release can be found here: http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2016-11-23-uks-pathology-services-at-tipping-point